Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical mo...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Hoek, Anita M., Verschuren, Lars, Caspers, Martien P. M., Worms, Nicole, Menke, Aswin L., Princen, Hans M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930243/
https://www.ncbi.nlm.nih.gov/pubmed/33658534
http://dx.doi.org/10.1038/s41598-021-83974-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930243/
https://www.ncbi.nlm.nih.gov/pubmed/33658534
http://dx.doi.org/10.1038/s41598-021-83974-8

Ejemplares similares